Patents by Inventor Jean-Michel Rondeau
Jean-Michel Rondeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140079719Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: November 20, 2013Publication date: March 20, 2014Applicant: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8617552Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: January 13, 2012Date of Patent: December 31, 2013Assignee: Novarts AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Publication number: 20120107325Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: January 13, 2012Publication date: May 3, 2012Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8119131Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: February 18, 2010Date of Patent: February 21, 2012Assignee: Novartis AGInventors: Franco E Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Patent number: 8093406Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.Type: GrantFiled: July 9, 2009Date of Patent: January 10, 2012Assignee: Novartis AGInventors: Emmanuelle Briard, Rainer Martin Lueoend, Rainer Machauer, Henrik Moebitz, Olivier Rogel, Jean-Michel Rondeau, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra
-
Publication number: 20110288057Abstract: The invention relates to the use of and mainly novel compounds of the formula I wherein the moieties are as defined in the description, which are useful as farnesyl pyrophosphate synthase modulators and e.g. in the treatment of proliferative diseases.Type: ApplicationFiled: October 12, 2009Publication date: November 24, 2011Applicant: Novartis AGInventors: Simona Cotesta, Joseph Fraser Glickman, Wolfgang Jahnke, Andreas Marzinzik, Silvio Ofner, Jean-Michel Rondeau, Thomas Zoller
-
Publication number: 20110257131Abstract: (Unsubstituted or substituted phenyl)-alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are disclosed. The compounds are able to inhibit excessive or inappropriate bone resorption. The compounds are of the formula I, wherein one of R1 and R2 are as defined in the specification, and can be in free form, in the form of an ester, and/or of a salt.Type: ApplicationFiled: December 21, 2009Publication date: October 20, 2011Applicant: NOVARTIS AGInventors: Simona Cotesta, Wolfgang Jahnke, Jean-Michel Rondeau, Sven Weiler, Leo Widler
-
Publication number: 20110224173Abstract: C2-C5-Alkyl-substituted [imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.Type: ApplicationFiled: May 26, 2011Publication date: September 15, 2011Applicant: NOVARTIS AGInventors: Sven Weiler, Leo Widler, Jean-Michel Rondeau, Simona Cotesta, Wolfgang Jahnke
-
Patent number: 7977323Abstract: C2-C5-Alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.Type: GrantFiled: November 26, 2008Date of Patent: July 12, 2011Assignee: Novartis AGInventors: Sven Weiler, Leo Widler, Jean Michel Rondeau, Simona Cotesta, Wolfgang Jahnke
-
Patent number: 7807155Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: GrantFiled: August 4, 2005Date of Patent: October 5, 2010Assignee: Novartis AGInventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Publication number: 20100215666Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: February 18, 2010Publication date: August 26, 2010Inventors: FRANCO E. DI PADOVA, HERMANN GRAM, HANS HOFSTETTER, MARGIT JESCHKE, JEAN-MICHEL RONDEAU, WIM VAN DEN BERG
-
Publication number: 20100144741Abstract: The invention relates to novel cyclic compounds of the formula (I), in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.Type: ApplicationFiled: November 22, 2007Publication date: June 10, 2010Inventors: Mathias Frederiksen, Rainer Martin Luond, Clive McCarthy, Henrik Moebitz, Jean-Michel Rondeau, Bernard Lucien Roy, Heinrich Rueeger
-
Publication number: 20100056490Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.Type: ApplicationFiled: July 9, 2009Publication date: March 4, 2010Inventors: Emmanuelle Briard, Rainer Martin Lueoend, Rainer Machauer, Henrik Moebitz, Olivier Rogel, Jean-Michel Rondeau, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra
-
Publication number: 20090280131Abstract: An IL-17 binding molecule, in particular an antibody to human IL-17, more preferably a human antibody to human IL-17 is provided, wherein the hypervariable regions of the heavy and light chains have amino acid sequences as defined, for use in the treatment of an IL-17 mediated disease or disorder, e.g. rheumatoid arthritis.Type: ApplicationFiled: August 4, 2005Publication date: November 12, 2009Inventors: Franco E. Di Padova, Hermann Gram, Hans Hofstetter, Margit Jeschke, Jean-Michel Rondeau, Wim Van Den Berg
-
Publication number: 20090247577Abstract: Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (disorder) that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound. The substituted pyrrolidine compounds are especially of the formula I, wherein the substituents are as defined in the specification.Type: ApplicationFiled: June 4, 2007Publication date: October 1, 2009Inventors: Olivier Rogel, Jean-Michel Rondeau, Heinrich Rueeger, Oliver Simic, Finton Sirockin, Marina Tintelnot-Blomley
-
Publication number: 20090143337Abstract: C2-C5-Alkyl-substituted [(imidazol-1-yl)-1-hydroxy-1-phosphono-ethyl]-phosphonic acids, as well as methods or processes for their manufacture, their use in the manufacture of pharmaceutical formulations, their use in the treatment of diseases, methods of using them in the treatment of diseases, pharmaceutical formulations encompassing them and/or the compounds for use in the treatment of diseases, are described. The compounds are able to inhibit excessive or inappropriate bone resorption and for the treatment of other diseases which are caused by excessive prenylation of target proteins, such as Hutchinson-Gilford progeria syndrome. The compounds are of the formula I, wherein one of R1 and R2 is hydrogen and the other is C2-C5-alkyl that is branched or unbranched, and can be in free form, in the form of an ester, and/or of a salt.Type: ApplicationFiled: November 26, 2008Publication date: June 4, 2009Applicant: NOVARTIS AGInventors: Sven Weiler, Leo Widler, Jean-Michel Rondeau, Simona Cotesta, Wolfgang Jahnke
-
Publication number: 20090099207Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free base form or in acid addition salt form, to their preparation, to their use as medicaments and to medicaments comprising them.Type: ApplicationFiled: February 14, 2007Publication date: April 16, 2009Inventors: Heinrich Rueeger, Clive McCarthy, Henrik Moebitz, Jean-Michel Rondeau, Marina Tintelnot-Blomley
-
Publication number: 20090054427Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.Type: ApplicationFiled: August 22, 2008Publication date: February 26, 2009Inventors: Emmanuelle Briard, Rainer Martin Lueoend, Rainer Machauer, Henrik Moebitz, Olivier Rogel, Jean-Michel Rondeau, Heinrich Rueeger, Marina Tintelnot-Blomley, Siem Jacob Veenstra
-
Publication number: 20080139449Abstract: The present invention relates to crystalline human farnesyl diphosphate synthase (FPPS), to the three-dimensional structure of free FPPS as well as the three-dimensional structures of FPPS in complex with substrates such as IPP (isopentenyl diphosphate) and/or with inhibitors such as Zometa® or Aredia®. Further, methods for preparing crystals of human FPPS are described. According to the invention the crystals can be used to determine the structures of FPPS homologs mutants, complexes with ligands, FPPS crystal forms and similar molecules of unknown structure. The invention further relates to the use of FPPS crystals to select new FPPS ligands, e.g. by X-ray screening and to design and/or identify inhibitors against FPPS. Furthermore, the invention relates to NMR methods for selecting and/or identifying new low molecular weight binders to FPPS, which represent new therapeutic agents.Type: ApplicationFiled: January 2, 2006Publication date: June 12, 2008Inventors: Wolfgang Jahnke, Jean-Michel Rondeau, Martin Geiser, Paul Ramage, Andre Strauss